A Study of Over 830,000 Patients Published on November 6, 2026

A study of over 830,000 patients published on November 6, 2026, in JAMA Network Open has found no evidence that β3 adrenergic agonists, a newer class of medication for overactive bladder (OAB), offer a lower risk of dementia compared to anticholinergic drugs.

The findings directly challenge a prevailing clinical assumption that β3 agonists are a safer, more neuroprotective choice for long-term OAB management. “In this large, national, EHR-based cohort study of over 830,000 adults with OAB, we found no evidence that β3 agonists were safer compared with anticholinergics with respect to incident dementia,” the study’s authors wrote.

The research, which analyzed electronic health record data from 2012 to 2025, was conducted by investigators at the Urology Institute of University Hospitals Cleveland Medical Center. The results were reported by outlets including 2 Minute Medicine, UA.News, and EMJ Reviews.

According to the study, the small differences observed in dementia risk between the drug classes were most consistent with “residual channeling bias,” a phenomenon in which clinicians, following guideline advice, may steer older adults or those perceived to be at higher cognitive risk toward the newer β3 agonists. This prescribing pattern could artificially inflate the dementia risk associated with those drugs.

Study finds no higher dementia risk from
Photo: UA.NEWS

830,393 Adults with OAB Tracked in Epic Cosmos

The researchers used the Epic Cosmos electronic health record database to identify 830,393 adults aged 40 to 90 who were newly diagnosed with OAB and initiated pharmacological treatment. The cohort was 70.5% female, with a median age of 67 years. Medications were categorized into three groups: high-risk anticholinergics (oxybutynin, tolterodine, solifenacin), low-risk anticholinergics (darifenacin, trospium, fesoterodine), and β3 agonists (mirabegron, vibegron).

During the follow-up period, 65,134 patients (7.8%) developed dementia, a diagnosis identified through clinical codes or prescriptions for dementia-specific medications. After adjusting for various factors using inverse probability of treatment weighting, the analysis produced several key results:

  • High-risk anticholinergics were associated with a significantly lower dementia risk than β3 agonists (hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.87–0.93).
  • High-risk anticholinergics also showed a lower dementia risk than low-risk anticholinergics (HR, 0.93; 95% CI, 0.90–0.96).
  • There was no statistically significant difference in dementia risk between low-risk anticholinergics and β3 agonists (HR, 0.97; 95% CI, 0.93–1.01).

The statistical tools used to assess the robustness of these findings, known as E-values, were low at 1.29 and 1.20. This indicates that relatively modest, unmeasured confounding factors could account for the observed differences between the drug classes.

A Study of Over 830,000 Patients Published on November 6, 2026
Photo: EMJ

Newer Bladder Drugs Show No Dementia Safety Edge

  • Despite previous beliefs, the new β3 agonist drugs for overactive bladder do not appear to be safer for the brain than older anticholinergic drugs.
  • The small differences in risk found in the study are likely due to doctors already giving the β3 drugs to sicker patients, not because the drugs themselves cause more dementia.
  • The study found that the total amount of time a person took an anticholinergic drug was not linked to a higher chance of developing dementia, even after more than a year of use.

Duration of Use and Dementia Risk

A key question for clinicians and patients has been whether the cumulative dose or duration of anticholinergic exposure increases dementia risk. To investigate this, the researchers conducted an exploratory “landmark analysis” of 395,709 patients, a method designed to eliminate a statistical bias known as “immortal time bias.”

The analysis found no evidence that longer exposure to anticholinergic medications, up to 400 days, was associated with an increased incidence of dementia.

The authors suggest that the observed pattern could be related to the underlying health of the patients, where those who are healthier and thus have a better prognosis are more likely to remain on their prescribed medications longer.

Contrasting Previous Research and Potential Explanations

These current results stand in contrast to a 2020 study of a population-based cohort, which indicated that patients with overactive bladder faced a higher likelihood of dementia when prescribed anticholinergics rather than beta-3 agonists.

A Study of Over 830,000 Patients Published on November 6, 2026
Photo: Renal and Urology News

According to the Cleveland team, the differences are likely attributable to variations in study design, including how immortal time bias and exposure were handled. They also propose a compelling alternative hypothesis: that OAB itself may be an early clinical sign of the same neurodegenerative or cerebrovascular processes that lead to dementia, rather than being caused by the medications used to treat it.

According to David Sheyn, urogynecologist and the study’s lead author, in comments reported by UA.News: “The results require replication before they can affect clinical guidelines. Beta-3 agonists are still considered the preferred choice when they can be used.”

The study’s publication comes at a time of close attention to the long-term cognitive effects of common medications. OAB is a highly prevalent condition, affecting up to one third of adults, and pharmacotherapy is a mainstay of management. The study's assertion that OAB may be an early marker of dementia also calls for integrated care pathways that manage both bladder symptoms and cognitive health simultaneously.

Medication Class Example Drugs 10-Year Dementia Risk (Weighted) Hazard Ratio vs. β3 Agonists
High-Risk Anticholinergics Oxybutynin, Tolterodine, Solifenacin 18.1% 0.90 (95% CI, 0.87–0.93)
Low-Risk Anticholinergics Darifenacin, Trospium, Fesoterodine N/A 0.97 (95% CI, 0.93–1.01)
β3 Adrenergic Agonists Mirabegron, Vibegron 20.0% Reference

Talk to Your Doctor Before Starting OAB Treatment

While this study addresses long-term dementia risk, the choice of OAB medication involves a comprehensive evaluation of an individual’s health. Anticholinergic medications may have short-term side effects related to memory and cognitive function; according to the study’s lead author, such symptoms resolve after the medication is discontinued.

Patients should consult a doctor about side effects from any OAB medication. It is also crucial to discuss any pre-existing cognitive conditions with a healthcare provider before starting a new treatment, as this study highlights the importance of personalized risk assessment over generalized class-based assumptions.

Conclusion and Future Research

New research from University Hospitals Cleveland Medical Center provides a real-world counterpoint to earlier studies suggesting a dementia risk advantage for β3 agonists. By highlighting the influence of prescribing bias and the potential role of OAB as a marker of underlying neurological decline, the study offers a more nuanced understanding of the relationship between these common drugs and long-term brain health.

As the lead author noted, these findings will need to be replicated in other populations and settings before they can meaningfully influence clinical practice. For now, the decision between anticholinergics and β3 agonists should continue to be based on a patient's individual comorbidities, side effect profile, and response to therapy, rather than on the assumption of a cognitive safety difference.

References

  • Sheyn D, Rhodes S, Mohamed Z, Hijaz A. Drug therapies and incidence of dementia among adults with overactive bladder. JAMA Netw Open. 2026;9(11):e2642026. doi:10.1001/jamanetworkopen.2026.42026
  • Welk B, McArthur E. A population-based cohort investigation into the comparative dementia risks associated with anticholinergic agents versus beta-3 agonists in patients diagnosed with overactive bladder. BJU Int. 2020;126(1):183-190. doi:10.1111/bju.15040
  • 2 Minute Medicine. “Use of β3 adrenergic agonists was not associated with a lower risk of dementia compared to anticholinergics in the management of overactive bladder (OAB).”
  • UA.News / News-Medical. Report on the study’s findings. https://ua.news
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Tarriela Refutes Zheng Zhihua’s Claim of Illegal Occupation of Ayungin Shoal

FAA Clears Dream Chaser Spaceplane Landings at Vandenberg, Kennedy